Trials / Completed
CompletedNCT02724644
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 375 (actual)
- Sponsor
- Endo Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The study will evaluate the safety, effectiveness, and immunogenicity of EN3835 in the treatment of adult women with Edematous Fibrosclerotic Panniculopathy (Commonly known as Cellulite).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | Injectable intervention |
| BIOLOGICAL | Placebo Comparator |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2016-03-31
- Last updated
- 2017-11-06
- Results posted
- 2017-11-06
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02724644. Inclusion in this directory is not an endorsement.